1
Hector Richard F, Collins Michael S: Use of anti-tnf to treat bacterial meningitis.. Miles, March 9, 1994: EP0585705-A1 (79 worldwide citation)

Bacterial meningitis infection in a mammal is treated by intravenous infusion of therapeutically effective amounts of monoclonal antibodies which bind to tumor necrosis factor alpha. Treatment can be initiated up to five hours after bacterial challenge and is preferably in combination with an antibi ...


2

3
Tsay Grace C, Collins Michael S: Vaccines for gram-negative bacteria and method for the preparation thereof.. Miles Lab, September 19, 1984: EP0118831-A2 (13 worldwide citation)

An immunizing composition is disclosed and comprises a detoxified polysaccharide from a gram-negative bacterium covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4 - 12 carbon moiety. To prepare the above immunizing agent. the lipid A portion of lipopolysacch ...


4
Collins Michael S, Opitz Hans Georg, Lundblad John L, Seng Richard L: Therapeutic igm concentrates.. Miles, December 13, 1989: EP0345543-A2 (7 worldwide citation)

Protective antibody compositions comprising at least 33% by weight of antibodies of the IgM type and substantially free of homologous isoagglutinins are highly active against gram negative pathogens in mammals. Such compositions are preferably polyclonal and prepared from human plasma, or may be a f ...


5
Champion Alexander B, Collins Michael S: An improved blood bag system incorporating quinolone carboxylic acid derivatives.. Miles, June 29, 1988: EP0272551-A2 (4 worldwide citation)

A method and system is disclosed for introducing antibacterial agents, for example, quinolone carboxylic acid derivatives into blood bag systems for preventing massive bacteria growth in stored blood and blood components. The quinolone carboxylic acid derivative can be added to a collection containe ...


6
Rutherford Richard L, Collins Michael S, Harmon Richard C: Protective antibodies to serotypic determinants of flagellar antigens.. Miles Lab, February 25, 1987: EP0211352-A2 (3 worldwide citation)

Monoclonal antibodies specific to serotypic determinants on the flagella of a microorganism and found to be useful in inhibiting motility.


7
Rousell Ralph H, Collins Michael S: Monoclonal antibodies in immune serum globulin.. Miles, August 16, 1990: EP0382031-A2 (1 worldwide citation)

Therapeutic efficacy of monoclonal antibodies can be enhanced by using plasma derived, polyclonal immune serum globulin as a vehicle for the monoclonal antibodies. Enhanced protective activity is demonstrated by using a combination of monoclonal antibodies specific to Pseudomonas aeruginosa in a pla ...


8
Tsay Grace C, Collins Michael S: Vaccines for gram-negative bacteria.. Miles, March 15, 1989: EP0306607-A1 (1 worldwide citation)

An immunizing composition is disclosed and comprises a detoxified polysaccharide from a gram-negative bacterium covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4 - 12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysacch ...


9
Collins Michael S, Roby Robert E: Serum-globuline ayant un titre eleve danticorps contre pseudomonas, High titer pseudomonas immune serum globulin. Miles, OGILVY RENAULT SENCRLSRL, CA1247527

Abstract of the Disclosure Normal plasma from donors who have not been vaccinated with a Pseudomonas vaccine or had a Pseudomonas infection can be screened for higher than normal titers of naturally occurring antibody to four of seven Fisher Immunotypes for Pseudomonas. Those plasmas with higher tit ...


10
Champion Alexander B, Collins Michael S: Addition de derives de lacide carboxylique quinilone aux sacs de sang, Blood bag system incorporating quinolone carboxylic acid derivatives. Miles, SWABEY OGILVY RENAULT, January 12, 1993: CA1312545

Inventor: ALEXANDER B. CHAMPION MICHAEL S. COLLINS Invention: AN IMPROVED BLOOD BAG SYSTEM INCORPORATING QUINOLONE CARBOXYLICACID DERIVATIVES Abstract of the Disclosure A method and system is disclosed for introducing anti-bacterial agents, for example, quinolone carboxylic acidderivatives into bloo ...